In an in vivo study, vandetanib (Figure 7) was reported to induce tumor regression in patient-derived xenograft ER-negative BC models, expressing high levels of EGFR or RET (rearranged during transfection) through the inhibition of EGFR phosphorylation. This evidence concerns the gene EGFR and breast cancer.